دورية أكاديمية
Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin).
| العنوان: | Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin). |
|---|---|
| المؤلفون: | Prager F; Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria., Michels S, Geitzenauer W, Schmidt-Erfurth U |
| المصدر: | Acta ophthalmologica Scandinavica [Acta Ophthalmol Scand] 2007 Dec; Vol. 85 (8), pp. 904-6. Date of Electronic Publication: 2007 Apr 13. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: Denmark NLM ID: 9507578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0420 (Electronic) Linking ISSN: 13953907 NLM ISO Abbreviation: Acta Ophthalmol Scand Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Blackwell Original Publication: Hvidovre, Denmark : Scriptor, c1995- |
| مواضيع طبية MeSH: | Genes, Dominant*, Choroidal Neovascularization/*etiology , Retinal Diseases/*complications , Retinal Diseases/*genetics, Adult ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/physiopathology ; Female ; Fundus Oculi ; Humans ; Retinal Diseases/diagnosis ; Retinal Diseases/physiopathology ; Visual Acuity |
| مستخلص: | Purpose: A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin). Methods: A 41-year-old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow-up. Results: At 16 month follow-up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity. Conclusion: Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD. |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20070417 Date Completed: 20080103 Latest Revision: 20151119 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/j.1600-0420.2007.00927.x |
| PMID: | 17433023 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1600-0420 |
|---|---|
| DOI: | 10.1111/j.1600-0420.2007.00927.x |